A Critical View of “On TB Vaccines, Patients’ Demands, and Modern Printed Media in Times of Biomedical Uncertainties: Buenos Aires, 1920–1950”

AbstractThe putative Pueyo ’s vaccine was a commercial venture that obtained marketing authorization in 1946, a turbulent period of Argentine history. After a few months, health authorities withdrew financial support from the state to buy the vaccine and required patients to sign a written consent to receive that product. A n independent investigation did not find any evidence of benefit in non-clinical and clinical evaluation of the putative vaccine.
Source: Journal of Bioethical Inquiry - Category: Medical Ethics Source Type: research

Related Links:

Publication date: January 2019Source: The Lancet Global Health, Volume 7, Issue 1Author(s): K du Preez, J A Seddon, H S Schaaf, A C Hesseling, J R Starke, M Osman, C J Lombard, R Solomons
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
Abstract Tuberculosis (TB) is the first cause of death from infectious diseases worldwide. Only a single anti-TB vaccine is currently available for clinical use, but its efficacy is not achieved with certainty. The aim of this work is to provide a basis for the rational design of a neo-glycoconjugate vaccine against TB. Structural characterization of recombinant antigenic proteins from Mycobacterium tuberculosis (MTB) Ag85B (rAg85B, variants, and semi-synthetic glycoconjugates) was initially carried out. Identification of antibody epitope analyses by proteolytic affinity-mass spectrometry and surface plasmon reson...
Source: Analytical and Bioanalytical Chemistry - Category: Chemistry Authors: Tags: Anal Bioanal Chem Source Type: research
Conclusions: Proteomic approach reveals key proteins participating in different species of Mycobacteria, and may be useful for discrimination between MTB and the BCG Tokyo172 infection.
Source: Journal of Global Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
Publication date: Available online 23 November 2018Source: Microbial PathogenesisAuthor(s): Kirti Pandey, Parul Bhatt, Medha, Swati Singh, Monika Sharma, Anil Chaudhry, Sadhna SharmaAbstractIt is well established that the current problem of tuberculosis (TB) can be combated by overcoming the drawbacks of the currently available BCG vaccine. This would involve incorporation of antigens that can control TB at all stages including the dormant phase which is generally ignored. Hence, DosR regulon proteins, which are expressed in latent infection, could prove to be very good vaccine candidates as they can possibly target the si...
Source: Microbial Pathogenesis - Category: Infectious Diseases Source Type: research
This study showed that MmaA4, HspR, and Erp proteins from MTB are successful in eliciting both humoral and cellular immune responses in mice. PMID: 30484328 [PubMed - as supplied by publisher]
Source: Acta Microbiologica et Immunologica Hungarica - Category: Microbiology Authors: Tags: Acta Microbiol Immunol Hung Source Type: research
The tuberculosis vaccine candidate M72/AS01E, which contains 2Mycobacterium tuberculosis proteins, provided 54.0% protection against active pulmonary tuberculosis in adults infected with latent tuberculosis infection, according to the results of a phase 2btrial reported in theNew England Journal of Medicine.
Source: JAMA - Category: General Medicine Source Type: research
Multiple ‐scale integrative analysis revealed the expression and regulatory networks of PE/PPE family antigens underlying the virulence and pathogenesis of Mtb, providing important clues for the discovery of new anti‐TB measures AbstractPE/PPE family antigens are distributed mainly in pathogenic mycobacteria and serve as potential antituberculosis (TB) vaccine components. Some PE/PPE family antigens can regulate the host innate immune response, interfere with macrophage activation and phagolysosome fusion, and serve as major sources of antigenic variation. PE/PPE antigens have been associated with mycobacteria pathogen...
Source: Journal of Cellular Physiology - Category: Cytology Authors: Tags: MINI ‐REVIEW Source Type: research
This systematic review and meta-analysis examines the safety and efficacy of bacillus Calmette-Gu érin vaccination at birth or later points in infants who are preterm and/or had low birth weights compared with ones who are full term and/or had normal birth weights.
Source: JAMA Pediatrics - Category: Pediatrics Source Type: research
Abstract Ranking above AIDS, tuberculosis (TB) is the ninth leading cause of death affecting and killing many individuals every year. Drugs' efficacy is limited by serials of problems such as multi-drug resistance (MDR) and extensively-drug resistance (XDR). Meanwhile, the only licensed vaccine BCG (Bacillus Calmette-Guérin) existing for over 90 years is not effective enough. Consequently, it is essential to develop novel vaccines for TB prevention and immunotherapy. This paper provides an overall review of the TB prevalence, immune system response against TB and recent progress of TB vaccine research and d...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
Conclusion: The strategy of optimizing immunoassay analysis is capable of detecting subset profiles that distinguish subjects with TST(+)/IGRA(-) and potential false(-) IGRA results.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Tuberculosis Source Type: research
More News: Marketing | Medical Ethics | Tuberculosis (BCG) Vaccine | Vaccines